UBS AM
IRON icon

UBS AM’s Disc Medicine IRON Stock Holding History

UBS AM’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.35M Buy
114,109
+3,219
+3% +$221K ﹤0.01% 1344
2026
Q1 		$7.09M Sell
110,890
-3,461
-3% -$240K ﹤0.01% 1393
2025
Q4 		$9.08M Buy
114,351
+22,971
+25% +$1.94M ﹤0.01% 1164
2025
Q3 		$6.04M Sell
91,380
-30,204
-25% -$1.8M ﹤0.01% 1285
2025
Q2 		$6.44M Buy
121,584
+25,027
+26% +$1.18M ﹤0.01% 1581
2025
Q1 		$4.79M Buy
96,557
+3,454
+4% +$192K ﹤0.01% 1600
2024
Q4 		$5.9M Buy
93,103
+74,454
+399% +$4.31M ﹤0.01% 1523
2024
Q3 		$916K Buy
18,649
+3,312
+22% +$155K ﹤0.01% 2437
2024
Q2 		$691K Buy
15,337
+10,487
+216% +$356K ﹤0.01% 2536
2024
Q1 		$302K Buy
+4,850
New +$314K ﹤0.01% 2395

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's IRON Position: Q2 2026 in Review

UBS AM increased its Disc Medicine (IRON) stake by 2.9% in Q2 2026, buying an estimated $221K and bringing the position to 114,109 shares worth $8.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1344.

UBS AM first reported a position in IRON in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.08M in Q4 2025. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • UBS AM held 114,109 shares of Disc Medicine worth $8.35M as of Q2 2026.
  • UBS AM bought 3,219 Disc Medicine shares in Q2 2026, an estimated $221K.
  • Disc Medicine made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1344 holding.
  • UBS AM first reported a position in Disc Medicine in Q1 2024 and has held it in 10 quarters since.
  • UBS AM's Disc Medicine position peaked at $9.08M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.